Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Magazine

Jean-Pierre Garnier


Since the $195 billion merger between rival British drug companies Glaxo Wellcome and SmithKline Beecham (GSK) closed last December, CEO Jean-Pierre Garnier has moved quickly to ensure that GlaxoSmithKline maintains its leading 6.9% share of the $317 billion global drug business. In the process, the 53-year-old French native is proving that drug mergers, often exercises in value destruction, can work, and work fast.

In GSK's inaugural first-quarter, pretax pharmaceutical profits soared 11%, to $2 billion, on sales of around $7 billion. Diabetes treatment Avandia and recently launched Seretide, an asthma medication, helped fuel profits. At the same time, Garnier, who is known as J.P., has already wrung $580 million in cost savings from overlapping businesses. And the stock? Up 12% since New Year's.

Garnier is determined to make the new GSK "king of science." So he has reshaped the company's massive research and development effort into competing teams to boost productivity. The payoff could be big: The company should launch 15 new drugs by 2005. For J.P., it's just the start.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus